8 citations
,
May 2025 in “Pharmaceuticals” In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
68 citations
,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
2 citations
,
November 2025 in “Biomedicines” This review discusses the dual regenerative and antimicrobial properties of platelet- and marrow-derived biologics, such as PRP and BMAC, which are used in tissue repair and regeneration. These biologics promote healing and reduce infection risk through growth factors, cytokines, and cellular components. They show significant regenerative effects in musculoskeletal conditions, wound healing, and cartilage repair. However, clinical outcomes are affected by preparation methods, patient factors, and lack of standardization. Despite their potential to reduce reliance on pain medications and improve function, these therapies face challenges like inconsistent protocols, limited long-term safety data, and regulatory issues. The review emphasizes the need for standardized procedures and further research to optimize their clinical use in pain medicine.
2 citations
,
December 2018 in “Journal of cosmetic dermatology” Higher CRBP1 levels are linked to more severe alopecia areata.
January 2024 in “Wiadomości Lekarskie” Augmented reality improves vascular surgery by reducing risks and operation times.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
87 citations
,
January 1996 in “Journal of cellular biochemistry” Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
2 citations
,
May 2025 in “Frontiers in Immunology” Ursolic acid may help develop new anti-inflammatory drugs by affecting immune cells.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
Finasteride treatment increased blood volume and reduced vessel leakiness in beagle prostates.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
29 citations
,
April 2019 in “Acta neuropathologica communications” Stopping mitochondrial respiration can prevent brain cancer spread in skin cancer patients, and plant compound β-sitosterol could help achieve this.
19 citations
,
December 2008 in “Arthritis Care & Research” The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
November 2009 in “Regenerative Medicine” The regenerative medicine industry saw business growth with new partnerships, clinical trials, and financial investments.
1 citations
,
April 2022 in “Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents” Biocompatible artificial hair is safe, effective, and improves quality of life for alopecia patients.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine may be effective for treating ashy dermatosis.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
13 citations
,
January 2010 in “Immunopharmacology and immunotoxicology” Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
52 citations
,
April 2013 in “Developmental Cell” Brg1 is crucial for hair growth and skin repair by maintaining stem cells and promoting regeneration.
4 citations
,
January 2023 in “Indian Dermatology Online Journal” A simple test can help diagnose a rare bruising disorder after ruling out other causes.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.